|
Post by ryster505 on Oct 29, 2018 17:11:19 GMT -5
|
|
|
Post by compound26 on Oct 29, 2018 17:13:31 GMT -5
www.receptorlife.com/receptor-holdings-inc-secures-29-million-funding-roundReceptor Holdings, Inc. Secures $29 Million Funding Round
PRESS RELEASE October 29, 2018 SEATTLE – Receptor Holdings, Inc. and its wholly-owned subsidiary, Receptor Life Sciences, a biopharmaceutical company developing cannabinoid medicines featuring distinct pharmaceutical drug delivery technologies, today announced that it raised $29 million in a combined convertible debt and Series A round of financing. Receptor controls patented and disruptive oral and inhaled drug delivery technologies that are validated by their use in FDA-approved products. In initial studies, Receptor’s oral dosage formulations facilitated rapid drug absorption from the GI tract with higher bioavailability than has been reported for existing oral cannabinoid products. Receptor’s inhalation technology combines a simple-to-use, breath-powered inhaler with dry powder cannabinoid formulations that provides ultra-rapid, precise and discreet delivery of cannabinoid medicines to the deep lung. “The closing of the Series A round will allow us to initiate IND-enabling studies in the United States and to formalize collaborations in Canada and Europe,” said Greg Wesner, Chief Executive Officer of Receptor Holdings. “The growing consensus is that cannabinoids have the potential to meet numerous and significant unmet medical needs for indications including epilepsy, chronic pain and post-traumatic stress disorder. By leveraging validated drug delivery technologies, we believe our products have the potential to set the standard of care for cannabinoid medicines in terms of onset of action, bioavailability and consistency.” ABOUT RECEPTOR HOLDINGS Receptor Holdings, Inc. owns or has exclusively licensed drug delivery technologies characterized by high bioavailability, rapid onset of action and lower variability and is applying these technologies to the burgeoning field of cannabinoid therapy. Its wholly-owned subsidiary, Receptor Life Sciences, is focused on the development of cannabinoid drugs regulated by the U.S. Food and Drug Administration. Receptor Holdings also plans to introduce its disruptive technologies to the non-prescription cannabinoid markets that are developing in Canada, Europe and elsewhere.
|
|
|
Post by celo on Oct 29, 2018 17:21:27 GMT -5
You know how many people are already using cannabinoid creams for joint pain and cannabinoid inhalation for stress or relaxation? A lot! It is becoming huge and I have only heard positive results from it's use. No THC CBDs is becoming very popular.
|
|
|
Post by tingtongtung on Oct 29, 2018 17:25:30 GMT -5
Is there a milestone due for MNKD on this event??
|
|
|
Post by veritasfiliatemporis on Oct 29, 2018 17:27:57 GMT -5
I see the trees have been replaced.. I suppose
|
|
|
Post by celo on Oct 29, 2018 17:28:39 GMT -5
"Receptor’s dry powder inhalation technology, Receptor AIR™, exclusively licensed from MannKind Corporation, resulted from Mr. Wesner’s experience as intellectual property counsel to MannKind. Mr. Wesner managed an exhaustive analysis of worldwide pulmonary drug delivery technologies and became convinced MannKind’s inhalation system is the only one capable of safely, reliably and precisely delivering cannabinoid-based drugs rapidly to the bloodstream. That insight led to Receptor and MannKind’s global partnership." www.receptorlife.com/leadership
|
|
|
Post by Omega on Oct 29, 2018 17:29:26 GMT -5
RLS - Leadership
GREGORY F. WESNER Chief Executive Officer
ORRIN DEVINSKY, M.D. Chief Medical Officer
ANDREA LEONE-BAY, PH.D. Chief Scientific Officer
|
|
|
Post by Omega on Oct 29, 2018 17:33:13 GMT -5
I love the pic of Mannkind's device Front and Center on the RLS Technology page: "Based on a best-in-class inhaled drug delivery platform"
|
|
|
Post by louaboardalia on Oct 29, 2018 17:33:48 GMT -5
Thanks for the post! Now we have to wait to see what develops...I have to say this was nicely timed...3 days in advance of the MNKD Conference Call on Nov. 1st. Hopefully this will be discussed in more detail then.
|
|
|
Post by uvula on Oct 29, 2018 17:37:48 GMT -5
Lots of stuff is happening all at once.
|
|
|
Post by falconquest on Oct 29, 2018 17:41:08 GMT -5
Dr. Andrea Leone-Bay, what a remarkable career!
|
|
|
Post by celo on Oct 29, 2018 17:41:11 GMT -5
The Hemp Business Journal estimated that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That's a 700% increase from 2016. In 2015, the market for consumer sales of hemp-derived CBD products was $90 million, plus another $112 million in marijuana-derived CBD products which were sold through dispensaries – bringing a total CBD market to $202 million last year. Matt Karnes of Greenwave Advisors is even more optimistic about the growth of the CBD market saying, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only -- this is in addition to the 28 states plus DC that have legalized medical marijuana.” www.forbes.com/sites/debraborchardt/2016/12/12/the-cannabis-market-that-could-grow-700-by-2020/#1b3aa1194be1
|
|
|
Post by centralcoastinvestor on Oct 29, 2018 17:49:29 GMT -5
This is a very interesting development. Wouldn’t that be something if Mike expanded on this on Thursday. I view this as very exciting news.
|
|
|
Post by peppy on Oct 29, 2018 17:50:42 GMT -5
The Hemp Business Journal estimated that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That's a 700% increase from 2016. In 2015, the market for consumer sales of hemp-derived CBD products was $90 million, plus another $112 million in marijuana-derived CBD products which were sold through dispensaries – bringing a total CBD market to $202 million last year. Matt Karnes of Greenwave Advisors is even more optimistic about the growth of the CBD market saying, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow CBD only -- this is in addition to the 28 states plus DC that have legalized medical marijuana.” www.forbes.com/sites/debraborchardt/2016/12/12/the-cannabis-market-that-could-grow-700-by-2020/#1b3aa1194be1 Accordingly, "industrial hemp" is defined in statute as "the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." Hemp legal to grow now. How do I apply to grow hemp? All first-time applicants must submit an application, a set of fingerprints, an Informed Consent Form to authorize the MDA to conduct a federal/state criminal background check on their behalf, a $37 payment, and a detailed map of your field. Fingerprints may be obtained from the Bureau of Criminal Apprehension (BCA) or your local sheriff or police department.
|
|
|
Post by peppy on Oct 29, 2018 17:54:58 GMT -5
www.receptorlife.com/receptor-holdings-inc-secures-29-million-funding-roundReceptor Holdings, Inc. Secures $29 Million Funding Round
PRESS RELEASE October 29, 2018 SEATTLE – Receptor Holdings, Inc. and its wholly-owned subsidiary, Receptor Life Sciences, a biopharmaceutical company developing cannabinoid medicines featuring distinct pharmaceutical drug delivery technologies, today announced that it raised $29 million in a combined convertible debt and Series A round of financing. Receptor controls patented and disruptive oral and inhaled drug delivery technologies that are validated by their use in FDA-approved products. In initial studies, Receptor’s oral dosage formulations facilitated rapid drug absorption from the GI tract with higher bioavailability than has been reported for existing oral cannabinoid products. Receptor’s inhalation technology combines a simple-to-use, breath-powered inhaler with dry powder cannabinoid formulations that provides ultra-rapid, precise and discreet delivery of cannabinoid medicines to the deep lung. “The closing of the Series A round will allow us to initiate IND-enabling studies in the United States and to formalize collaborations in Canada and Europe,” said Greg Wesner, Chief Executive Officer of Receptor Holdings. “The growing consensus is that cannabinoids have the potential to meet numerous and significant unmet medical needs for indications including epilepsy, chronic pain and post-traumatic stress disorder. By leveraging validated drug delivery technologies, we believe our products have the potential to set the standard of care for cannabinoid medicines in terms of onset of action, bioavailability and consistency.” ABOUT RECEPTOR HOLDINGS Receptor Holdings, Inc. owns or has exclusively licensed drug delivery technologies characterized by high bioavailability, rapid onset of action and lower variability and is applying these technologies to the burgeoning field of cannabinoid therapy. Its wholly-owned subsidiary, Receptor Life Sciences, is focused on the development of cannabinoid drugs regulated by the U.S. Food and Drug Administration. Receptor Holdings also plans to introduce its disruptive technologies to the non-prescription cannabinoid markets that are developing in Canada, Europe and elsewhere. Quote: to meet numerous and significant unmet medical needs for indications including epilepsy, chronic pain and post-traumatic stress disorder. Reply: Epilepsy is the ticket here.
|
|